Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 912345...Last »

Opposition mounts to genetic modification of human embryos

A group of U.S. scientists and activists on Monday called for a global ban on the use of new tools to edit the genes of human embryos, in a report issued a day before a major international meeting in Washington to discuss the ethical and policy issues surrounding the technology.   A technological innovation that […]

Read More »

Exercise as young adult tied to heart health decades later

(Reuters Health) – Young adults who exercise may have a lower risk of cardiovascular disease and higher survival odds decades later than their peers who aren’t as active early in life, a U.S. study suggests. Fitness has long been linked to a reduced risk of heart disease in older adults. The new study, however, offers […]

Read More »

New York is first U.S. city with salt warning on restaurant menus

A tiny salt shaker symbol that warns certain meals are high in sodium will appear, starting Tuesday, on menus in chain restaurants in New York City, the first U.S. city to take the step in an effort to combat heart disease and stroke. Any menu item containing more than 2,300 milligrams (0.08 oz) of sodium, […]

Read More »

FDA approves new Bristol-Myers treatment for multiple myeloma

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp’s Revlimid and common anti-inflammatory drug […]

Read More »

Supreme Court rejects Covidien bid to restore patent verdict against Ethicon

The U.S. Supreme Court on Monday rejected an appeal by Covidien LP seeking to restore a $176 million patent infringement verdict against Johnson & Johnson subsidiary Ethicon Inc.   In refusing to hear the case, the high court left in place a December 2014 ruling by the U.S. Court of Appeals for the Federal Circuit […]

Read More »

Servier Slashes 610 Jobs in Company Reorganization

SURESNES, France– Privately-held Servier, a French pharmaceutical company, will slash 610 employees as it faces increased competition and a tougher regulatory environment, Reuters reported Friday.   Reuters said the firm, which employs approximately 21,000 worldwide, said it has faced financial losses due to the end of patents, competition from generic drugs, regulated price controls, increased […]

Read More »

Beijing aims to refill medicine chest with Made in China drugs

China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and aging population.   Given the 10 years or more it typically takes to bring a new medicine to market, original “Made in […]

Read More »

Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Focused On GPCR Targets Across Multiple Therapeutic Areas

LONDON and BOSTON, November 30, 2015 /PRNewswire/ — Heptares Therapeutics (“Heptares”), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines […]

Read More »

Pfizer Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at […]

Read More »

Roche pulls out of superbug antibiotic project

Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating “superbug” infections, the company said on Sunday.   Roche had agreed in 2013 to pay privately held partner Polyphor up to 500 million Swiss francs ($485.3 million) for rights to the product, marking a rare foray by a […]

Read More »

FDA declines expanded approval for Bristol-Myers’ Opdivo drug

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer. Bristol-Myers said it received a so-called complete response letter from the health regulator, which indicated the need for additional data in the BRAF mutated patient […]

Read More »

Mixed drinks with diet beverages may boost breath alcohol levels

People who mix alcohol and diet drinks end up with more alcohol on their breath, according to a new study. People who drank vodka mixed with diet soda had higher alcohol concentrations on their breath than those who drank the same amount of vodka mixed with regular soda, researchers write in Drug and Alcohol Dependence. […]

Read More »

Exclusive: Lazard works with Sanofi on $12.7 billion animal health unit deal – sources

Investment bank Lazard is working with Sanofi’s management to prepare a sale or listing of its Merial animal health unit, aiming to land the leading advisory job for the deal, which could value the business at up 12 billion euros ($12.7 billion), sources familiar with the matter said. Lazard is expected to win the role […]

Read More »

EU approves Roche’s Cotellic in combo therapy against skin cancer

The European Union gave its green light to Roche’s Cotellic for use in combination with the drug Zelboraf against advanced melanoma, the company said on Wednesday.   Roche is counting on Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015. It has been […]

Read More »

Pfizer’s Lyrica shows no relief from post-traumatic nerve pain

Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study. The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday. Currently, there is no approved treatment in the United […]

Read More »

Why Price Gouging May Come to an End

(And a way to save some drug companies from themselves) November 25, 2015 By Karl Thiel for BioSpace.com   Price gouging in the pharmaceutical industry has been much in the news lately. There was, of course, the recent case of Turing Pharma and its 5,400 percent increase on the price on Daraprim, a decades-old drug. […]

Read More »

Shkreli’s Turing Pharma Rolls Out a 50% Price Cut for Daraprim

New York and Zug, Switzerland-based Turing Pharmaceuticals LLC announced yesterday a 50 percent cut in its prices for toxoplasmosis drug Daraprim.   Turing and its controversial chief executive officer Martin Shkreli became the focus of a national discussion of drug pricing in August after it acquired Daraprim from IMPAX Laboratories, Inc. (IPKL) for $55 million. […]

Read More »

Research raises questions over ADHD drug effects

Researchers voiced concern on Wednesday about poor quality studies on the popular ADHD treatment Ritalin, saying evidence of some benefits, but also of sleep problems and appetite loss, suggests the drug should be prescribed with caution. Ritalin is sold by Swiss pharmaceutical firm Novartis NOVN.VX, known generically as methylphenidate and also sold under the brand […]

Read More »

FDA panel says BioMarin DMD drug data not persuasive enough

A panel of outside advisers to the U.S. Food and Drug Administration indicated that efficacy data from BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle wastage disorder was not persuasive enough to warrant approval. The FDA panel did not officially vote on an approval of the drug, but 15 out of 17 […]

Read More »

Ad agency legend Al Nickel passes away

Medical advertising veteran Al Nickel passed away unexpectedly on Saturday at the age of 72 years. Mr. Nickel was a visionary and principal member of New York-based healthcare communications agency LLNS (Lyons, Lavey, Nickel, Swift). Mr Nickel is a member of the Medical Advertising Hall of Fame. He was inducted into the MAHF as part […]

Read More »

Page 1 of 912345...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation